Immatics veröffentlicht Daten aus laufender Phase-1-Zelltherapie-Studie ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME
October 10, 2022 07:36 ET
|
Immatics N.V.
Live-Webcast am Montag, den 10. Oktober, um 14:30 Uhr MESZ Klinische Validierung von PRAME als Multi-Tumor-Zielstruktur mit großem Potenzial für TCR-basierte Zelltherapien: Bestätigte...
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...